127 related articles for article (PubMed ID: 26044568)
1. The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma.
Bourlon MT; Flaig TW
Curr Drug Targets; 2016; 17(2):196-205. PubMed ID: 26044568
[TBL] [Abstract][Full Text] [Related]
2. Androgen receptor promotes the migration and invasion of upper urinary tract urothelial carcinoma cells through the upregulation of MMP-9 and COX-2.
Chen CC; Hsieh TF; Chang CH; Ma WL; Hung XF; Tsai YR; Lin MH; Zhang C; Chang C; Shyr CR
Oncol Rep; 2013 Aug; 30(2):979-85. PubMed ID: 23715826
[TBL] [Abstract][Full Text] [Related]
3. Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder.
Boorjian SA; Heemers HV; Frank I; Farmer SA; Schmidt LJ; Sebo TJ; Tindall DJ
Endocr Relat Cancer; 2009 Mar; 16(1):123-37. PubMed ID: 18845648
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of Elf5 is associated with epithelial-mesenchymal transition in urothelial cancer.
Wu B; Cao X; Liang X; Zhang X; Zhang W; Sun G; Wang D
PLoS One; 2015; 10(1):e0117510. PubMed ID: 25629735
[TBL] [Abstract][Full Text] [Related]
5. Role of the androgen receptor in urothelial cancer.
Inoue S; Mizushima T; Miyamoto H
Mol Cell Endocrinol; 2018 Apr; 465():73-81. PubMed ID: 28652170
[TBL] [Abstract][Full Text] [Related]
6. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
7. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes.
Olsen JR; Azeem W; Hellem MR; Marvyin K; Hua Y; Qu Y; Li L; Lin B; Ke X; Øyan AM; Kalland K
BMC Cancer; 2016 Jul; 16():377. PubMed ID: 27378372
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
9. Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research.
Necchi A; Lo Vullo S; Giannatempo P; Raggi D; Perrone F; Nicolai N; Catanzaro M; Biasoni D; Torelli T; Piva L; Stagni S; Salvioni R; Mariani L; Colecchia M
Clin Genitourin Cancer; 2018 Apr; 16(2):e403-e410. PubMed ID: 29111177
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor inducing bladder cancer progression by promoting an epithelial-mesenchymal transition.
Jitao W; Jinchen H; Qingzuo L; Li C; Lei S; Jianming W; Zhenli G
Andrologia; 2014 Dec; 46(10):1128-33. PubMed ID: 24329492
[TBL] [Abstract][Full Text] [Related]
11. Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.
Nakata D; Nakayama K; Masaki T; Tanaka A; Kusaka M; Watanabe T
Prostate; 2016 Dec; 76(16):1536-1545. PubMed ID: 27473672
[TBL] [Abstract][Full Text] [Related]
12. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
13. Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Sugita S; Kawashima H; Tanaka T; Kurisu T; Sugimura K; Nakatani T
Oncol Rep; 2004 Jun; 11(6):1273-9. PubMed ID: 15138566
[TBL] [Abstract][Full Text] [Related]
14. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan NP; Liu Y; Majumder S; Warren MR; Parker CE; Mohler JL; Earp HS; Whang YE
Proc Natl Acad Sci U S A; 2007 May; 104(20):8438-43. PubMed ID: 17494760
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
16. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A
Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577
[TBL] [Abstract][Full Text] [Related]
17. Transcribed ultraconserved region Uc.63+ promotes resistance to cisplatin through regulation of androgen receptor signaling in bladder cancer.
Sekino Y; Sakamoto N; Ishikawa A; Honma R; Shigematsu Y; Hayashi T; Sentani K; Oue N; Teishima J; Matsubara A; Yasui W
Oncol Rep; 2019 May; 41(5):3111-3118. PubMed ID: 30864720
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor signaling in prostate cancer.
Culig Z; Santer FR
Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
[TBL] [Abstract][Full Text] [Related]
19. CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (flAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy.
Sun H; Mediwala SN; Szafran AT; Mancini MA; Marcelli M
Horm Cancer; 2016 Jun; 7(3):196-210. PubMed ID: 26957440
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
